SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amicus Therapeutics, Inc. & Encourages Investors with Losses...
December 01 2016 - 2:28PM
Business Wire
Goldberg Law PC, a national shareholder rights litigation firm,
announces that it is investigating Amicus Therapeutics, Inc.
(“Amicus” or the “Company”) (Nasdaq: FOLD) concerning possible
violations of federal securities laws.
If you purchased or otherwise acquired Amicus shares and would
like more information regarding the investigation, we encourage you
to contact Michael Goldberg or Brian Schall, of
Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles,
CA 90067, at 800-977-7401, to discuss your rights without cost to
you. You can also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The investigation is centered on whether Amicus and some of its
officers and/or directors have committed violations of Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
Amicus announced post-market on November 28, 2016 that its oral
drug Galafold (migalastat), used to treat Fabry disease, failed to
meet the U.S. Food and Drug Administration's criteria for an
expedited review, and that approval for the drug will be delayed
until at least 2020. The Company expects to start clinical trials
by next year, and trial data is expected to be available by
2019.
On this news, Amicus stock fell $1.81, or 21.75%, to close at
$6.51 on November 29, 2016, causing investors serious harm.
If you have any questions concerning your legal rights, please
immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com, or email us
at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201006273/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.com
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024